Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.
Adult
Aged
Chemotherapy, Adjuvant
Databases, Factual
Disease-Free Survival
Female
Humans
Lymphocyte Count
Lymphocytes
/ drug effects
Lymphopenia
/ blood
Middle Aged
Monocytes
/ drug effects
Neoadjuvant Therapy
/ adverse effects
Neoplasm Staging
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Triple Negative Breast Neoplasms
/ blood
Tumor Microenvironment
circulating immune biomarkers
lymphocytes
monocytes
neoadjuvant chemotherapy
triple negative breast cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
20
05
2020
revised:
05
07
2020
accepted:
15
07
2020
pubmed:
7
8
2020
medline:
21
7
2021
entrez:
7
8
2020
Statut:
ppublish
Résumé
Lymphopenia has been associated with inferior cancer outcomes, but there is limited data in breast cancer. We describe the effects of neoadjuvant chemotherapy on circulating immune cells and its association with pathological complete response (pCR) rates in triple negative breast cancer (TNBC). We constructed a database of patients with early stage TNBC treated with neoadjuvant chemotherapy. Circulating lymphocytes and monocytes were assessed before and after neoadjuvant chemotherapy. These were correlated with pCR rates and disease-free survival (DFS) using Fisher's exact test, logistic regression, and the log-rank test. From 2000 to 2015, we identified 95 eligible patients. Median age was 50; 29 (31%) were treated with platinum-containing chemotherapy; and 66 (69%) with nonplatinum-containing chemotherapy (anthracycline-taxane, or either alone). About 32 (34%) patients achieved a pCR; and 33 (35%) had recurrence events. Median follow-up time was 47 months. No significant associations were found between changes in lymphocytes and pCR or DFS. There was a correlation between lower monocyte levels after neoadjuvant chemotherapy and pCR (mean monocyte 0.56 in those with no-pCR vs 0.46 in those with pCR, P = .049, multivariate P = .078) and DFS (median DFS in highest monocyte quartile was 30 vs 107 months in lowest quartile, P = .022, multivariate P = .023). In patients who received nonplatinum regimens, DFS was better among those who had larger decreases in monocytes. Development of lymphopenia from neoadjuvant chemotherapy was not associated with pCR in patients with TNBC. However, lower absolute circulating monocytes after neoadjuvant chemotherapy was associated with improved outcomes.
Sections du résumé
BACKGROUND
Lymphopenia has been associated with inferior cancer outcomes, but there is limited data in breast cancer. We describe the effects of neoadjuvant chemotherapy on circulating immune cells and its association with pathological complete response (pCR) rates in triple negative breast cancer (TNBC).
METHODS
We constructed a database of patients with early stage TNBC treated with neoadjuvant chemotherapy. Circulating lymphocytes and monocytes were assessed before and after neoadjuvant chemotherapy. These were correlated with pCR rates and disease-free survival (DFS) using Fisher's exact test, logistic regression, and the log-rank test.
RESULTS
From 2000 to 2015, we identified 95 eligible patients. Median age was 50; 29 (31%) were treated with platinum-containing chemotherapy; and 66 (69%) with nonplatinum-containing chemotherapy (anthracycline-taxane, or either alone). About 32 (34%) patients achieved a pCR; and 33 (35%) had recurrence events. Median follow-up time was 47 months. No significant associations were found between changes in lymphocytes and pCR or DFS. There was a correlation between lower monocyte levels after neoadjuvant chemotherapy and pCR (mean monocyte 0.56 in those with no-pCR vs 0.46 in those with pCR, P = .049, multivariate P = .078) and DFS (median DFS in highest monocyte quartile was 30 vs 107 months in lowest quartile, P = .022, multivariate P = .023). In patients who received nonplatinum regimens, DFS was better among those who had larger decreases in monocytes.
CONCLUSIONS
Development of lymphopenia from neoadjuvant chemotherapy was not associated with pCR in patients with TNBC. However, lower absolute circulating monocytes after neoadjuvant chemotherapy was associated with improved outcomes.
Identifiants
pubmed: 32757467
doi: 10.1002/cam4.3358
pmc: PMC7541144
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6954-6960Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Oncotarget. 2017 Dec 14;8(69):114268-114280
pubmed: 29371985
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
pubmed: 17438091
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Am J Clin Pathol. 2016 Jun;145(6):871-8
pubmed: 27298399
J Ovarian Res. 2014 Feb 08;7:19
pubmed: 24507759
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Front Immunol. 2014 May 12;5:197
pubmed: 24860567
Breast Cancer Res. 2015 Aug 05;17:101
pubmed: 26243145
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
J Breast Cancer. 2013 Mar;16(1):32-9
pubmed: 23593079
Cancer. 2007 May 1;109(9):1721-8
pubmed: 17387718
J Breast Cancer. 2019 Jan 02;22(1):38-51
pubmed: 30941232
Clin Cancer Res. 2018 Jun 15;24(12):2851-2858
pubmed: 29581131
Clin Cancer Res. 2019 Aug 1;25(15):4644-4655
pubmed: 31061067
Cancer Med. 2020 Oct;9(19):6954-6960
pubmed: 32757467
Ann Oncol. 2016 Feb;27(2):249-56
pubmed: 26598540
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
BMC Cancer. 2012 Jul 23;12:306
pubmed: 22824040
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell Death Differ. 2014 Jan;21(1):15-25
pubmed: 23787994
J Natl Compr Canc Netw. 2015 Oct;13(10):1225-31
pubmed: 26483062
Cancer Res. 2013 Apr 15;73(8):2480-92
pubmed: 23436796